pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ASTRAZENECA · news · pharmadog
← back to ASTRAZENECA
News mentioning ASTRAZENECA
363
stories
15h
Biogen’s big lupus bet gets boost from new durability data for skin disease
biospace
20h
How AI is transforming biopharma manufacturing facilities of the future
biopharma dive
1d
Opinion: FDA must ensure American patients can access new and experimental drugs
biospace
3d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
3d
Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone
endpoints
4d
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
4d
Pfizer’s eczema drug clears skin in mid-stage trial
biopharma dive
4d
BMS reports liver injury events in lung disease program, with key readout near
biospace
5d
STAT+: HHS announces new efforts to speed up, expand clinical trials with AI
stat
5d
$40M in tax incentives expected to generate 1,600+ life sciences jobs in Massachusetts
biospace
5d
STAT+: Three biotech updates, including accusations of theft and and a new lobbying leader
stat
5d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
5d
Opinion: America’s biotech race with China must be won at home
stat
6d
STAT+: Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property
stat
6d
STAT+: Overton won’t get a vote before midterms
stat
6d
Canadian $5M accelerated clinical trial program cuts start-up to 45 days
fiercebiotech
6d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
6d
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
6d
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
7d
AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos
fiercebiotech
7d
AstraZeneca buys a $2B stake in Summit, taking equity in bet on cancer drug
endpoints
7d
Merck licenses a KRAS G12D inhibitor for $400M upfront
endpoints
7d
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
biopharma dive
7d
Roche drops muscle-sparing obesity antibody after flunked interim analysis
fiercebiotech
11d
Chutes & Ladders—Travere chief makes way for former Amicus CEO
fiercebiotech
12d
9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe
biopharma dive
12d
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's study
biospace
12d
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
biospace
12d
Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALS
biospace
13d
Amgen reports a Phase 3 win with Sjögren’s drug candidate
biopharma dive
← prev
page 1 of 13
next →
